Clinical trials: Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
- Condition Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
- Trial name
- NCT04380753
- Testing
- AMG 510
- Where
- 4 sites in Hong Kong, Taiwan
- Volunteers
- 12 people
- Sponsor
- Amgen